^
Association details:
| Biomarker: | MET exon 14 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | CKD-702 (c-MET inhibitor, EGFR antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 3044: The novel bi-specific antibody CKD-702 is a potential agent for NSCLC patients with aberrant cMET and EGFR signaling
Published date:
05/15/2020
Excerpt:
There are various types of cMET activation in NSCLC patients, including point mutations and amplification...CKD-702 showed complete tumor regression as monotherapy in tumor models that have primary/secondary activating EGFR mutations and cMET amplification. Also, CKD-702 resulted in complete tumor regression in models where cMET is activated by either skipping of exon 14 or amplification...In summary, CKD-702 is confirmed to inhibit tumors with activated cMET pathway such as cMET amplification and exon 14 skipping as well as with EGFR-activating mutations.
DOI:
10.1158/1538-7445.AM2020-3044
